Arrowhead Research Newswire

Arrowhead Research Newswire

Comprehensive Real-Time News Feed for Arrowhead Research.

Results 1 - 20 of 138 in Arrowhead Research

  1. Arbutus Biopharma Taken Off Of Chardan's Sell ListRead the original story w/Photo

    Thursday Jun 16 | Benzinga

    Chardan has upgraded Arbutus Biopharma Corp to Neutral following its underperformance versus Arrowhead Pharmaceuticals Inc and the S&P biotech index. Over the past month, Arbutus shares have dropped 26 percent, in contrast to both Arrowhead shares and the SPDR S&P Biotech Index .

    Comment?

  2. Arrowhead Research Corp (NASDAQ:ARWR) Receives Average Rating of "Buy" from AnalystsRead the original story w/Photo

    Monday Jun 13 | AmericanBankingNews.com

    Shares of Arrowhead Research Corp have been given an average rating of "Buy" by the six analysts that are covering the company. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company.

    Comment?

  3. Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple...Read the original story

    Thursday Jun 9 | Information Technology

    Arrowhead Pharmaceuticals Inc. today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus infection. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single doses of ARC-521 in healthy volunteers and the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV.

    Comment?

  4. Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare ConferenceRead the original story

    Friday Jun 3 | Information Technology

    Arrowhead Pharmaceuticals Inc. today announced that chief operating officer and head of R&D Bruce Given, M.D., will present at the Jefferies 2016 Healthcare Conference on June 10, 2016 at 10:30 a.m. EDT. Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page under the Investors section of the Arrowhead website.

    Comment?

  5. Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare ConferenceRead the original story w/Photo

    Friday Jun 3 | Freshnews

    Arrowhead Pharmaceuticals Inc. today announced that chief operating officer and head of R&D Bruce Given, M.D., will present at the Jefferies 2016 Healthcare Conference on June 10, 2016 at 10:30 a.m. EDT. Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page under the Investors section of the Arrowhead website.

    Comment?

  6. Global RNAi For Therapeutic Consumption Market New Research Study 2016Read the original story

    Thursday Jun 2 | Emailwire.com

    ... 8.2.2.3 Type III 8.2.3 Capacity, Production, Price, Cost, Gross and Revenue 8.2.4 Contact Information 8.3 Arrowhead Research 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Type I 8.3.2.2 Type II 8.3.2.3 Type III 8.3.3 ...

    Comment?

  7. Arrowhead Research Corp (ARWR) Coverage Initiated at Chardan CapitalRead the original story w/Photo

    May 22, 2016 | Daily Political

    ... Chardan Capital's price target points to a potential upside of 121.40% from the company's current price. Arrowhead Research Corp (NASDAQ:ARWR) opened at 5.42 on Thursday. The stock's market capitalization is $324.98 million. Arrowhead Research Corp ...

    Comment?

  8. Brokerages Set Arrowhead Research Corp (NASDAQ:ARWR) PT at $10.27Read the original story w/Photo

    May 22, 2016 | Daily Political

    Arrowhead Research Corp has received an average rating of "Buy" from the six research firms that are currently covering the company. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company.

    Comment?

  9. Arrowhead Research Corp (ARWR) Coverage Initiated at Chardan CapitalRead the original story w/Photo

    May 21, 2016 | AmericanBankingNews.com

    ... on the stock. Jefferies Group reaffirmed a "hold" rating and issued a $4.75 target price on shares of Arrowhead Research Corp in a report on Wednesday, May 11th. Vetr raised shares of Arrowhead Research Corp from a "hold" rating to a "strong-buy" ...

    Comment?

  10. Arrowhead Research Corp (NASDAQ:ARWR) Receives Average Recommendation of "Buy" from BrokeragesRead the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    Shares of Arrowhead Research Corp have been given an average rating of "Buy" by the six analysts that are currently covering the firm. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company.

    Comment?

  11. 5 Reasons Arrowhead Pharma Is A Hepatitis B LeaderRead the original story w/Photo

    May 19, 2016 | Benzinga

    Arrowhead Pharmaceuticals Inc reported positive data in a Phase II study of its lead product ARC-520 for the treatment of hepatitis B surface antigen [HBsAg] in HB envelope antigen-positive [HBeAg+] HBV patients. Chardan Capital's Madhu Kumar initiated coverage of the company with a Buy rating and price target of $12.

    Comment?

  12. Arrowhead Research Corp (ARWR) Coverage Initiated by Analysts at Chardan CapitalRead the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    ... recently modified their holdings of ARWR. BlackRock Fund Advisors boosted its position in shares of Arrowhead Research Corp by 0.7% in the first quarter. BlackRock Fund Advisors now owns 2,299,574 shares of the company's stock valued at $11,084,000 ...

    Comment?

  13. Arrowhead Research Corp (ARWR) Earns Hold Rating from Jefferies GroupRead the original story w/Photo

    May 16, 2016 | Daily Political

    Several hedge funds have recently modified their holdings of ARWR. Geode Capital Management LLC boosted its stake in shares of Arrowhead Research Corp by 8.3% in the first quarter.

    Comment?

  14. Arrowhead Research Corp (ARWR) to Post Q3 2016 Earnings of ($0.38)...Read the original story w/Photo

    May 14, 2016 | Daily Political

    Arrowhead Research Corp - Investment analysts at Jefferies Group raised their Q3 2016 EPS estimates for shares of Arrowhead Research Corp in a research report issued to clients and investors on Wednesday, Zacks Investment Research reports. Jefferies Group analyst E. Yang now forecasts that the firm will earn per share for the quarter, up from their prior forecast of .

    Comment?

  15. Jefferies Group Analysts Increase Earnings Estimates for Arrowhead Research CorpRead the original story w/Photo

    May 13, 2016 | AmericanBankingNews.com

    Arrowhead Research Corp - Investment analysts at Jefferies Group upped their Q3 2016 earnings estimates for Arrowhead Research Corp in a report released on Wednesday, Zacks Investment Research reports. Jefferies Group analyst E. Yang now forecasts that the firm will post earnings of per share for the quarter, up from their prior forecast of .

    Comment?

  16. Research Analysts Issue Forecasts for Arrowhead Research Corp's FY2019 EarningsRead the original story w/Photo

    May 12, 2016 | AmericanBankingNews.com

    Arrowhead Research Corp - Equities research analysts at Jefferies Group decreased their FY2019 earnings per share estimates for Arrowhead Research Corp in a research report issued to clients and investors on Wednesday, Zacks Investment Research reports. Jefferies Group analyst E. Yang now forecasts that the brokerage will earn $1.83 per share for the year, down from their prior forecast of $1.84.

    Comment?

  17. Arrowhead Pharma Reports Fiscal 2016 Second Quarter ResultsRead the original story

    May 10, 2016 | BioSpace

    Arrowhead Pharmaceuticals Inc. today announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

    Comment?

  18. Jefferies Group Reiterates "Hold" Rating for Arrowhead Research CorpRead the original story w/Photo

    May 11, 2016 | AmericanBankingNews.com

    ... target price would suggest a potential downside of 16.96% from the company's current price. Shares of Arrowhead Research Corp ( NASDAQ:ARWR ) opened at 5.54 on Wednesday. The company's market capitalization is $330.33 million. The firm's 50-day ...

    Comment?

  19. Arrowhead Research Corp (ARWR) Earns Hold Rating from Jefferies GroupRead the original story w/Photo

    May 11, 2016 | AmericanBankingNews.com

    ... Group's price target suggests a potential downside of 16.96% from the company's current price. Shares of Arrowhead Research Corp ( NASDAQ:ARWR ) opened at 5.72 on Wednesday. The company's market capitalization is $341.07 million. Arrowhead Research ...

    Comment?

  20. Arrowhead's (ARWR) CEO Christopher Anzalone on Q2 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    May 10, 2016 | Seeking Alpha

    ... advancing products through clinical development to bring innovative new medicines to patients. The name Arrowhead Research was simply no longer an accurate representation of the Company. Arrowhead Pharmaceuticals reflects the progress we're making ...

    Comment?